Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Boston Scientific Corporation

Share:
Related BSX
Needham Calls Boston Scientific's Results Just 'Decent'
Boston Scientific Posts In-Line Q1 Earnings, Issues Weak Outlook
Boston Scientific Lotus Valve System: Key to Clinical Efficacy - Analyst Blog (Zacks)

In a report published Wednesday, Citigroup reiterated its Buy rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $7.30 to $8.20.

Citigroup noted, “BSX's shares have moved up significantly faster than we expected since last Thanksgiving, but we still see room for the stock on a fundamental basis as trends are improving and the peer group valuation has moved up. Plus, we still believe the call option on Durata being removed from the market is largely underappreciated.”

Boston Scientific Corporation closed on Tuesday at $7.10.

Latest Ratings for BSX

DateFirmActionFromTo
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform
Apr 2015RBC CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...